Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
“Publication of our ASPEN-06 data in Nature Medicine, a prestigious peer-reviewed scientific journal, further validates the clinical potential of evorpacept and reinforces our biomarker-driven development strategy,” said Barbara Klencke, M.D., Chief Medical Officer of ALX Oncology. “Data from ASPEN-06 demonstrated that patients whose tumors retained HER2 expression and had high CD47 expression experienced the greatest benefit from evorpacept-based therapy, supporting our hypothesis that evorpacept can enhance the activity of HER2-directed treatment regimens and highlights CD47 expression as a potential predictive biomarker. These findings further strengthen our conviction in the ongoing Phase 2 ASPEN-09-Breast clinical trial in HER2-positive metastatic breast cancer, which remains on track for a topline data readout from 80 patients in mid-2027.”
Share:
More News
Jian Peng, PhD, CEO of Earendil Labs, said: “Genentech is a pioneer in defining modern biologics cancer medicine. Earendil Labs is building an AI-driven high-throughput biology platform that effectively integrates AI directly into biologics research and development—from predictive protein modeling and generative protein design to rapid experimental validation. By combining
“The IDMC’s recommendation to continue our Phase 2 MRD study without modification provides important independent validation of the favorable safety profile we have consistently observed across our clinical development program,” said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “Across our completed and ongoing clinical studies, we have
“These Phase 3 results reinforce the potential of ZENBEXUS to advance treatment for patients with relapsed or refractory multiple myeloma,” said Cristian Massacesi, executive vice president, chief medical officer and head of development, Bristol Myers Squibb. “As the first therapy in multiple myeloma to demonstrate superiority on an MRD-negative complete
“Initiating IND-enabling studies is a defining milestone for Beactica and for the BEA‑17 programme,” said Dr Per Källblad, Chief Executive Officer of Beactica Therapeutics. “With a first-in-class mechanism and compelling preclinical efficacy in combination with standard of care, we are now executing the rigorous safety and manufacturing programme that will